Trial Profile
A Comparative Open-Label Multicentre Clinical Trial To Assess The Efficacy And Safety Of A New Therapy With Cultured Chimeric Skin For The Treatment Of Skin Lesions In Patients With Epidermolysis Bullosa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs CX 501 (Primary)
- Indications Epidermolysis bullosa; Epidermolysis bullosa dystrophica
- Focus Therapeutic Use
- Acronyms TCEB
- Sponsors Cellerix; TiGenix
- 21 May 2014 New trial record